Info
2016.11.07
SanBio Presents Interim Results of the First Intracerebral Stem Cell Transplant Study for Stroke in the United States
News Release
2016.10.26
First Patient is Enrolled in Global STEMTRA Trial for Traumatic Brain Injury in Japan（187KB）
Info
2016.10.17
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio will speak on a panel at AusBiotech 2016 on October 25 in Melbourne, Australia
Info
2016.09.16
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio will speak at th 75th Annual Meeting of the Japan Neurosurgical Society on September 29 in Fukuoka, Japan
News Release
2016.07.11
First Patient is Randomized in STEMTRA Trial For Traumatic Brain Injury（92KB）
News Release
2016.06.27
SanBio Presents Interim Results of Chronic Stroke Phase 1/2a Clinical Trial at International Society of Stem Cell Research Annual Meeting（92KB）
Info
2016.06.03
Publication “Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study”Gary K. Steinberg, Douglas Kondziolka, Lawrence R. Wechsler, L. Dade Lunsford, Maria L. Coburn, Julia B. Billigen, Anthony S. Kim, Jeremiah N. Johnson, Damien Bates, Bill King, Casey Case, Michael McGrogan, Ernest W. Yankee, Neil E. Schwartz
News Release
2016.06.03
SanBio publishes interim 12-month Phase 1/2a clinical trial results in the leading medical journal, Stroke（112KB）
News Release
2016.05.16
SanBio Granted Key Patent in Treatment for Macular Degeneration（90KB）
Info
2016.04.06
Keita Mori, CEO of SanBio, will speak at New Economy Summit 2016 ”Session 1: Medical Innovation” in Tokyo on April 7
News Release
2024.11.15
The Results of the First Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2024.09.05
Positive Results of Key Development Product SB623 for Chronic Effects of Traumatic Brain Injury, including Sustained Motor Function Improvement up to 48 weeks, published in Neurology
News Release
2024.07.31
SanBio Obtains Marketing Approval for “AKUUGO🄬 Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)
News Release
2024.07.29
Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US
News Release
2024.07.10
[Results of Basic Research] Publication of an Article on the Neuronal Activity and Network Formation Promotion of the Key Development Product SB623
News Release
2024.06.20
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.06.12
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.03.26
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.03.18
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2023.12.14
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Media
2022.04.08
On April 7, NeurologyLive published an interview with Dr. Peter McAllister regarding the final analysis of the Phase 2 STEMTRA trial.
Media
2018.04.20
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, publishes report in the leading medical journal, Stroke
Info
2024.11.11
MORI, President & CEO, will be a panelist at “Navigating Biopharma Innovation Across the Pacific” hosted by the U.S. Embassy and the Japan Society of Northern California on November 11
Info
2022.12.22
Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury
Info
2021.02.22
Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan
Info
2021.01.06
SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Info
2019.12.16
Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
Info
2018.12.27
【Announcement】SanBio will present at the 37th Annual J.P. Morgan Healthcare Conference
Info
2018.08.28
【Announcement】SanBio will be featured on NHK WORLD – JAPAN “Medical Frontiers – The Brain Can Be Regenerated” on September 4 (Tue) 4 times a day, Japan timeIt is available for watching on the Internet.
Info
2018.01.10
SanBio presented at the 36th Annual J.P. Morgan Healthcare Conference
Info
2017.11.22
Keita Mori, CEO of SanBio will speak at 2017 World Alliance Forum in San Francisco on November30
Info
2017.11.22
SanBio will present at 2nd DIA Cell Therapy Products Symposium in Japan on December 15"Quality of Regenerative Medical Products -What do we need to start a clinical study in Japan? -" Takehiko Kaneko, Medical Director & Head of Clinical Development Japan, SanBio Co., Ltd.
